OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Holdings Lifted by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,774,443 shares of the medical instruments supplier's stock after purchasing an additional 521,400 shares during the quarter. Renaissance Technologies LLC owned approximately 3.72% of OraSure Technologies worth $10,016,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Jane Street Group LLC increased its position in OraSure Technologies by 6.4% in the third quarter. Jane Street Group LLC now owns 296,194 shares of the medical instruments supplier's stock worth $1,265,000 after buying an additional 17,758 shares during the period. Barclays PLC lifted its position in OraSure Technologies by 182.6% in the 3rd quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier's stock valued at $836,000 after purchasing an additional 126,503 shares during the last quarter. Geode Capital Management LLC boosted its stake in OraSure Technologies by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,797,814 shares of the medical instruments supplier's stock valued at $7,678,000 after purchasing an additional 32,929 shares during the period. Franklin Resources Inc. grew its position in OraSure Technologies by 28.5% in the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier's stock worth $1,091,000 after purchasing an additional 59,723 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of OraSure Technologies by 28.1% in the third quarter. Principal Financial Group Inc. now owns 66,060 shares of the medical instruments supplier's stock valued at $282,000 after purchasing an additional 14,480 shares during the period. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered OraSure Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th.

OraSure Technologies Trading Up 3.1 %

OSUR stock traded up $0.09 during trading on Tuesday, hitting $2.96. The company had a trading volume of 406,471 shares, compared to its average volume of 878,357. The firm has a market capitalization of $221.41 million, a price-to-earnings ratio of 19.73 and a beta of 0.76. The business has a 50 day moving average of $3.37 and a 200 day moving average of $3.72. OraSure Technologies, Inc. has a fifty-two week low of $2.69 and a fifty-two week high of $5.59.

OraSure Technologies declared that its board has authorized a stock buyback plan on Monday, March 24th that allows the company to buyback $40.00 million in shares. This buyback authorization allows the medical instruments supplier to buy up to 15.6% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.

Insider Transactions at OraSure Technologies

In other news, Director John P. Kenny bought 47,659 shares of the business's stock in a transaction on Thursday, February 27th. The stock was purchased at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the transaction, the director now directly owns 70,915 shares of the company's stock, valued at approximately $224,800.55. This trade represents a 204.93 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Manner Carrie Eglinton purchased 78,625 shares of the stock in a transaction dated Thursday, February 27th. The shares were purchased at an average price of $3.15 per share, for a total transaction of $247,668.75. Following the completion of the transaction, the chief executive officer now owns 1,259,664 shares in the company, valued at $3,967,941.60. This trade represents a 6.66 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 190,284 shares of company stock valued at $600,348. Company insiders own 3.90% of the company's stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.